TASE:KMDABiotechs
Kamada (TASE:KMDA) Stock Quietly Ignores A Stronger Profit Run Rate
The market has treated Kamada like just another small biotech, with the stock roughly flat over the past week and slightly weaker over three months, even as the latest report lands. That calm reaction sits beside a quarter built around one clear story. Q2 2026 revenue reached US$54.9m and net income came in at US$9.3m, which marks the strongest profit trend in the recent history provided.
This is the sentiment gap investors now need to judge. Is a quiet share price move the right response to...